You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

CORRECTION article

Front. Immunol., 06 March 2025

Sec. Vaccines and Molecular Therapeutics

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1566389

Corrigendum: Mannose-modified erythrocyte membrane-encapsulated chitovanic nanoparticles as a DNA vaccine carrier against reticuloendothelial tissue hyperplasia virus

    YF

    Yangyang Feng 1,2

    FT

    Feng Tang 1,2

    SL

    Sheng Li 1,2

    DW

    Daiyan Wu 1,2

    QL

    Qianqian Liu 1,2

    HL

    Hangyu Li 1,2

    XZ

    Xinnan Zhang 1,2

    ZL

    Ziwei Liu 1,2

    LZ

    Linzi Zhang 1,2

    HF

    Haibo Feng 1,2*

  • 1. College of Animal Husbandry and Veterinary Medicine, Southwest Minzu University, Chengdu, China

  • 2. Key Laboratory of Ministry of Education and Sichuan Province for Qinghai-Tibetan Plateau Animal Genetic Resource Reservation and Utilization, Southwest-Minzu University, Chengdu, China

Article metrics

View details

943

Views

313

Downloads

In this published article, there was an error in Figure 3 as published. The incorrect image for group PBS, CS-gp90@M, and CS-gp90@M-M in Figure 3B was uploaded by mistake. The corrected Figure 3 and its caption appears below.

Figure 3

Figure 3

CS-gp90@M-M uptake by macrophages. (A) CLSM image of DiD-stained CS-gp90@M and CS-gp90@M-M nanoparticles up take by macrophages in vitro. Macrophage solution (8 × 104 cells/mL) was added to a 24-well plate, and 50 μL of DiD-stained CS-gp90@M and CS-gp90@M-M (200 μg/mL) nanoparticles were added and incubated for 8 h. Then, the cells were stained with DAPI dye and washed twice for 20 min. The cells were mounted using glycerol (90%) and observed by CLSM. Blue fluorescence represents DAPI-stained nuclei and red fluorescence represents DID-stained CS-gp90@M and CS-gp90@M-M nanoparticles. (B) The uptake of CS-gp90@M-M nanoparticles by macrophages using an IVIS instrument. Macrophages were added to a 6-well plate and cultured for 24 h. DiD-stained CS-gp90@M (50 μL) or CS-gp90@M-M (200 μg/mL) nanoparticles were added to macrophages (5 × 105) in a Petri dish for 8 h. The cells were collected and the intracellular fluorescence intensity of DID was determined using the IVIS instrument. The image shows the fluorescence intensity of the cellular uptake of CS-gp90@M and CS-gp90@M-M nanoparticles by macrophages. (C) The average radiant efficiency of the macrophage uptake of nanoparticles.

In this published article, there was an error in the legend for Figure 6 as published. The incorrect body and organ image for group CS-gp90@M-M at 168h in Figure 6A and Figure 6C was incorrectly uploaded. The corrected Figure 6 and its caption appears below.

Figure 6

Figure 6

Release and biodistribution of CS-gp90@M-M NPs in vivo. (A, B)In vivo fluorescence images of chicks and the attenuation of the fluorescent dyes over time (C–F) Direct imaging of excised organs. Live animal imaging of chicks. The vaccine formulation was stained using a Cy5.5 fluorescent dye and chicks were immunized with CS-gp90@M-M and CS-gp90@M NPs. Live-animal imaging and fluorescence intensity in chicks at 24, 48, 72, and 168 h after injection was determined using an in vivo optical imaging system (A, B). Direct imaging and fluorescence intensity of the bursa, spleens, and livers of the injected chicks was determined at 12, 24, 72, 120, and 168 h after injection (C–F).

In the published article, there was an error in Figure 8 as published. The incorrect use of pathological sections of spleen in the CS-gp90@M group were uploaded in Figure 8. The corrected Figure 8 and its caption appears below.

Figure 8

Figure 8

Analysis of potential in vivo toxicity. H&E staining of the lungs, heart, spleen, liver, and kidneys of vaccinated chicks on day 28 after immunization. Magnification: 100×, scale bars: 100 μm.

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

reticuloendothelial virus bionic, chitosan, erythrocyte membrane, mannose modification, delivery system

Citation

Feng Y, Tang F, Li S, Wu D, Liu Q, Li H, Zhang X, Liu Z, Zhang L and Feng H (2025) Corrigendum: Mannose-modified erythrocyte membrane-encapsulated chitovanic nanoparticles as a DNA vaccine carrier against reticuloendothelial tissue hyperplasia virus. Front. Immunol. 16:1566389. doi: 10.3389/fimmu.2025.1566389

Received

24 January 2025

Accepted

20 February 2025

Published

06 March 2025

Volume

16 - 2025

Edited and reviewed by

Bingdong Zhu, Lanzhou University, China

Updates

Copyright

*Correspondence: Haibo Feng,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics